Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 232,612,197 papers from all fields of science
Search
Sign In
Create Free Account
monoclonal antibody 806
Known as:
mAb 806
, mAb-806
, DEPATUXIZUMAB
Expand
A humanized monoclonal antibody (MoAb) against human epidermal growth factor receptor (EGFR) with antineoplastic activity. Depatuxizumab targets the…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
4 relations
Narrower (1)
ABT-806
Broader (1)
Monoclonal Antibodies
NCIt Antineoplastic Agent Terminology
antigen binding
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
ACTR-21. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF DEPATUXIZUMAB MAFODOTIN (ABT-414) IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (AMP) NEWLY DIAGNOSED GLIOBLASTOMA…
A. Lassman
,
S. Pugh
,
+27 authors
M. Mehta
Neuro-Oncology
2019
Corpus ID: 209227630
Approximately 50% of nGBMs harbor EGFR-amp. Depatuxizumab mafodotin (depatux-m) is an antibody drug conjugate: a monoclonal…
Expand
2019
2019
Phase I/II study of depatuxizumab mafodotin (ABT-414) monotherapy or combination with temozolomide in Japanese patients with/without EGFR-amplified recurrent glioblastoma.
Y. Narita
,
Y. Muragaki
,
+12 authors
K. Mishima
Journal of Clinical Oncology
2019
Corpus ID: 190885608
2065 Background: The poor prognosis of glioblastoma (GBM; WHO grade IV) results from a high rate of disease recurrence and lack…
Expand
2018
2018
Clinical and Histological Characterization of Toxic Keratopathy From Depatuxizumab Mafodotin (ABT-414), an Antibody-Drug Conjugate: [RETRACTED].
Brian A. Lee
,
Michael S. Lee
,
Amanda C. Maltry
,
J. Hou
Cornea
2018
Corpus ID: 44113714
PURPOSE To report the first histological characterization of microcyst-like epithelial keratopathy (MEK) associated with…
Expand
2018
2018
P01.071 Genomic profiling identifies tubulin mutations that may predict response to depatuxizumab mafodotin in patients with glioblastoma
A. Lassman
,
L. Roberts-Rapp
,
+7 authors
M. Bent
Neuro-Oncology
2018
Corpus ID: 81897985
2018
2018
Abstract A028: Biomarker analysis in a phase 1 study of the antibody-drug conjugate ABBV-221 in patients with solid tumors likely to overexpress the epidermal growth factor receptor (EGFR)
E. Calvo
,
J. Cleary
,
+8 authors
A. Tolcher
2018
Corpus ID: 81664303
Background: Aberrant EGFR plays a vital role in the oncogenesis of multiple tumor types. ABBV-221 is a 2 nd -generation antibody…
Expand
2018
2018
HGG-15. PHASE 2 NESTED COHORT STUDY OF DEPATUXIZUMAB MAFODOTIN IN CHILDREN WITH HIGH GRADE GLIOMA AND DIFFUSE INTRINSIC PONTINE GLIOMA WITH EGFR AMPLIFICATION
M. Bent
,
W. Dinjens
,
+7 authors
D. Hargrave
Neuro-Oncology
2018
Corpus ID: 81356269
2018
2018
ACTR-21. MANAGEMENT OF OCULAR SIDE EFFECTS IN PATIENTS WITH EGFR-AMPLIFIED GLIOBLASTOMA RECEIVING DEPATUXIZUMAB MAFODOTIN
Stella Kim
,
G. Moazami
,
+4 authors
M. Macsai
Neuro-Oncology
2018
Corpus ID: 59205702
2017
2017
PATH-29. MOLECULAR DETERMINANTS ASSOCIATED WITH RESPONSE AND RESISTANCE TO DEPATUXIZUMAB MAFODOTIN (ABT-414) IN PATIENTS WITH RECURRENT GLIOBLASTOMA
A. Lassman
,
L. Roberts-Rapp
,
+15 authors
A. Scott
2017
Corpus ID: 79750487
2016
2016
Depatuxizumab mafodotin. Anti-EGFR antibody-drug conjugate, Treatment of glioblastoma multiforme
Z. Gajdosik
2016
Corpus ID: 76987122
2004
2004
Anti-EGFR monoclonal antibody 806 to enter early-phase clinical trials
2004
Corpus ID: 195146051
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE